Effects of cardiovascular disease on pharmacokinetics.
The pathophysiologic changes occurring in cardiovascular disease can affect the kinetics of drugs in several different ways. The present review examines these modifications and the underlying mechanisms. The kinetics of specific agents, such as antiarrhythmic, antihypertensive, cardiotonic, and other drugs are considered, and the clinical implications are outlined. The clinician should be aware of these modifications, because they require an adjustment of the dosage regimen. A rational basis for a correct therapeutic choice can be provided by adequate knowledge of these modifications.
Rodighiero
V
V
Department of Pharmacology, University of Padova, Italy.
D000318:Adrenergic beta-Agonists / Q000493:pharmacokinetics*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000493:pharmacokinetics*; D000889:Anti-Arrhythmia Agents / Q000493:pharmacokinetics*; D000959:Antihypertensive Agents / Q000493:pharmacokinetics*; D002121:Calcium Channel Blockers / Q000493:pharmacokinetics*; D002316:Cardiotonic Agents / Q000493:pharmacokinetics*; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D004232:Diuretics / Q000493:pharmacokinetics*; D006801:Humans
D000318:Adrenergic beta-Agonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000889:Anti-Arrhythmia Agents; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D004232:Diuretics